The Caring Ambassadors supports individuals in gaining control of their healthcare, regardless of the illness they face.

We provide information, tools, and resources to help those with any long-term disease not only manage their health care after a diagnosis, but improve their quality of life and capacity for healing. As an advocacy organization, we both fight for patient rights and work to build a new generation of patient and healthcare champions. Our disease specific programs for Hepatitis C and Lung Cancer have been helping people obtain the support, assistance, and information they need for over 20 years.

Are you part of the Elimination movement?

Get Test! Get Cured!

Days to Hepatitis C Elimination.








To receive our weekly news updates in your inbox, CLICK HERE

Recent News

Week Ending December 10, 2018

Oregon Aims to Eliminate Hepatitis C Infections
“The state has the highest mortality rate in the country but a move by the Oregon Health Authority to expand expensive treatment could wipe out the virus, if medical modeling is correct.”

Earlier Hepatitis C Detection Could Enable Shorter Treatment
“Successful treatment of recently acquired hepatitis C virus (HCV) genotype 1 infection in 8 weeks, with a regimen currently approved for 12 weeks, adds to growing evidence that early detection could enable shorter, less costly treatment and more rapid reduction of the infectious viral pool.”

Mavyret achieves 97% SVR in real-world cohort of patients with HCV
“Mavyret demonstrated 97% sustained virologic response in a large, real-world cohort of patients with hepatitis C over an 8-week course and extended 12-week to 16-week courses, according to recently published data.”

Hepatitis C Present in Nasal, Rectal Fluids in High Viral Load Patients
“Hepatitis C virus (HCV) is present in the rectal and nasal fluids of infected patients with high viral loads even if blood is not, according to new research. The findings mean sharing of drug tools and unprotected sex could lead to transmission of the virus in some cases.”

A Bitter Pill to Swallow: Why Medication Safety Is Critical in Hepatitis C Treatment
“Approximately 71 million people globally are chronically infected with HCV, resulting in 399,000 deaths each year from HCV-related complications.1 In the United States, more than three million people are chronically infected, resulting in treatment-related costs of approximately $8 billion annually.2 In addition to its tremendous economic burden, HCV treatment results in many opportunities for medication errors to occur.”

Finding and Treating the Young Hepatitis C Patient
“Deaths per persons in the United States have dropped by 22% since 1990, a study published in April of this year found. But how people are dying is also constantly changing—sometimes at a more severe rate.”

Recent News

Week Ending December 10, 2018

Lung Cancer and the Young Adult Nonsmoker
“When it comes to lung cancer, recent statistics published by the National Cancer Institute show progress in the right direction.”

Researchers extend effectiveness of immunotherapy to more lung cancer patients
“Immunotherapy, the strategy for triggering the patient’s own immune system to attack cancer, is proving effective for more tumour types, although to varying degrees. In lung cancer, immunotherapy had proven to extend survival rates for only some variants of the disease.”

A newly discovered marker could allow quick diagnosis and lung cancer treatment
“An exciting study published in Science Translational Medicine has identified a novel protein which could aid in early diagnosis and lung cancer treatment.”

FDA approves Genentech drug for lung cancer
“Genentech, a member of the Roche Group, on Thursday said the U.S. Food and Drug Administration approved Tecentriq and chemotherapy for some patients with a certain type of lung cancer.”

Roche’s lung cancer combo treatment wins FDA approval
“Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq (atezolizumab) immunotherapy in combination with Avastin (bevacizumab) and chemotherapy won US Food and Drug Administration approval as a first-line treatment for a type of lung cancer.”


Mutation Testing for All Patients With NSCLC

Various Forms of Disease Progression in Advanced NSCLC

Recent News

Week Ending December 10, 2018

Foot reflexology to improve sleep quality, research says
“A study, published in the journal Complementary Therapies in Clinical Practice, states that foot reflexology is more effective than back massage in improving the quality of sleep. The researchers evaluated the efficacy of foot reflexology in improving sleep quality and reducing fatigue in individuals that require hemodialysis treatments.“

Complementary Therapies for Prostate Cancer Treatment
“Mr. Smith comes to the clinic for his first round of radia­tion for prostate cancer. During check-in, he mentions that he just started taking selenium because his daughter read that it has anticancer effects and may help shrink his tumor. He asks if this works and if it’s safe.”

Most patients lie to their doctors, study finds
“Are you always candid when talking with your doctor? For example, do you give your doctor an honest accounting of how often you exercise or drink alcohol? And do you speak up when you disagree with one of your doctor’s recommendations for improving your health?”

Maryland researchers receive grant to study the brain-to-gut connection in schizophrenia
“Researchers at the University of Maryland School of Medicine’s (UMSOM) Maryland Psychiatric Center (MPRC) and Institute for Genome Sciences (IGS), along with researchers at the University of Maryland School of Pharmacy (UMSOP), have been awarded a collaborative five-year $1.78 million grant to study the brain-to-gut connection in schizophrenia.”